Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,515 shares of the biotechnology company’s stock after purchasing an additional 1,700 shares during the period. Handelsbanken Fonder AB’s holdings in Sarepta Therapeutics were worth $3,102,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Manchester Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. lifted its stake in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank raised its position in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter worth about $36,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $105.56 on Tuesday. Sarepta Therapeutics, Inc. has a 1 year low of $101.15 and a 1 year high of $173.25. The firm has a 50 day moving average price of $117.11 and a 200 day moving average price of $123.14. The company has a market cap of $10.08 billion, a price-to-earnings ratio of 84.45 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Guggenheim lifted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Evercore ISI cut their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Robert W. Baird cut their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a “hold” rating and a $136.00 target price for the company. Finally, StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.